Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLLJacob D. Soumerai, Deborah M. Stephens, Jacqueline C. Barrientos et al.|Blood Advances|2024Cited by 19
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's SyndromeJennifer L. Crombie, Matthew S. Davids, Lisa Brennan et al.|Blood|2020Cited by 14
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJeongsook Yoon, Inhye E. Ahn, Yinglu Zhou et al.|Blood Advances|2025Cited by 12
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLJennifer L. Crombie, Matthew S. Davids, Svitlana Tyekucheva et al.|Blood|2019Cited by 9
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)Christine E. Ryan, Matthew S. Davids, Jennifer L. Crombie et al.|Blood|2022Cited by 8